Probucol: A Review of its Pharmacological Properties and Therapeutic Use in Patients with Hypercholesterolaemia

[1]  W. Parsons.  Effect of probucol in hyperlipidemic patients during two years of administration. , 1978, American heart journal.

[2]  M. Verstraete.  Antiplatelet Agents in Coronary Disease: Are They of Prophylactic Value? , 1978, Drugs.

[3]  Y. Huang,et al.  Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia. , 1977, Archives of internal medicine.

[4]  G. Rosenhamer,et al.  Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid. , 1977, Atherosclerosis.

[5]  H. S. Sodhi,et al.  Probucol: A new cholesterol‐lowering drug effective in patients with type II hyperlipoproteinemia , 1976, Clinical pharmacology and therapeutics.

[6]  H. B. Brown,et al.  The additive effect of probucol on diet in hyperlipidemia , 1974, Clinical pharmacology and therapeutics.

[7]  R. S. Harris,et al.  Long‐Term Oral Administration of Probucol [4, 4‘‐(Isopropylidenedithio) bis (2, 6‐di‐t‐Butylphenol)] (DH‐581) in the Management of Hypercholesterolemia * , 1974, Journal of the American Geriatrics Society.

[8]  J. Lewis,et al.  Sensitization to epinephrine-induced ventricular fibrillation produced by probucol in dogs. , 1973, Toxicology and applied pharmacology.

[9]  J. Molello,et al.  Toxicity of (4,4'-(isopropylidenedithio)bis(2,6-di-t-butylphenol)), probucol, in mice, rats, dogs and monkeys: demonstration of a species-specific phenomenon. , 1973, Toxicology and applied pharmacology.

[10]  C. H. Duncan,et al.  The additive effects of clofibrate and probucol (DH-581) on rat serum cholesterol. , 1973, Atherosclerosis.

[11]  T. Miettinen.  Mode of action of a new hypocholesteraemic drug (DH-581) in familial hypercholesteraemia. , 1972, Atherosclerosis.

[12]  M. Dacquisto,et al.  Biphenabid (Probucol): a new hypocholesterolemic agent. , 1971, Current therapeutic research, clinical and experimental.

[13]  J. Vester,et al.  Endocrine and metabolic indices during administration of a lipophilic bis‐phenol, probucol , 1971, Clinical pharmacology and therapeutics.

[14]  O. Brusco,et al.  [Action of the new hypocholesteremic agent DH-581 (dithiobisphenol) in humans]. , 1971, Prensa medica argentina.

[15]  D. Kritchevsky.  Newer hypolipidemic agents. , 1971, Federation proceedings.

[16]  D. Kritchevsky,et al.  Influence of 4,4'-(Isopropylidenedithio)bis(2,6-di-t-butylphenol) (DH-581) on Experimental Atherosclerosis in Rabbits 1 , 1971, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[17]  J. W. Barnhart,et al.  Hypocholesterolemic effect of 4,4'-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) (probucol). , 1970, The American journal of clinical nutrition.

[18]  R. Bradford,et al.  The effect of [4,4'-(isopropylidenethio)bis(2,6-di-t-butylphenol)] (DH-581) on serum lipids and lipoproteins in human subjects. , 1969, Metabolism: clinical and experimental.

[19]  B. Rifkind,et al.  Lipid Lowering Drugs and Hyperlipidaemia , 2012, Drugs.

[20]  P. Scott,et al.  Lipid Lowering Drugs and Coronary Heart Disease , 2012, Drugs.

[21]  J. W. Barnhart,et al.  An overview of the biochemical pharmacology of probucol , 2006, Lipids.

[22]  Nash Dt.  Probucol, a new cholesterol lowering drug. , 1975 .

[23]  T. Miettinen,et al.  Treatment of severe and mild hypercholesterolaemia with probucol and neomycin. , 1975, Postgraduate medical journal.

[24]  J. Sack,et al.  Probucol in the long-term treatment of hypercholesterolaemia. , 1973, Current medical research and opinion.